RxDoctor Payments Data

Mihir Maniar, DO

Internal Medicine · Eatontown, NJNPI 1659387264

Payments from drug & device makers

$9,733in general payments, 2019–2025

Across 655 payments — averaging $14.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$952
  • Pfizer$800
  • AstraZeneca$739
  • GSK$523
  • Lilly USA, LLC$518
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$9,733100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,733 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$207,222
Medicare patients
583
Services billed
2,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide205$257,728
EliquisApixaban138$130,243
MounjaroTirzepatide65$66,681
XareltoRivaroxaban59$54,192
JardianceEmpagliflozin34$29,556
FarxigaDapagliflozin Propanediol24$27,504
LinzessLinaclotide15$13,486
CrestorRosuvastatin Calcium21$11,248
Janumet XrSitagliptin Phos/Metformin Hcl12$11,046
Breo ElliptaFluticasone/Vilanterol13$10,663
SynthroidLevothyroxine Sodium76$8,036
Carvedilol ErCarvedilol Phosphate13$6,314
Rosuvastatin Calcium481$5,810
VytorinEzetimibe/Simvastatin13$4,970
Icosapent Ethyl15$4,970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$3,267$257,728205 claims
PfizerEliquis, Paxlovid$800$134,530160 claims
Lilly USA, LLCMounjaro$518$66,68165 claims
Johnson & JohnsonXarelto$101$54,19259 claims
AstraZenecaFarxiga, Crestor$739$38,75145 claims
Boehringer IngelheimJardiance$29$29,55634 claims
AbbVieLinzess, Synthroid$952$21,52291 claims
MerckJanumet Xr$344$11,04612 claims
GSKBreo Ellipta$523$10,66313 claims
NovartisDiovan$16$4,76813 claims
Almatica Pharma LLCSertraline Hcl$19$1,381120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Eatontown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →